Navigation Links
Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Date:11/15/2011

olicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting.  

Forward-Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements, and are based on Cadence's current beliefs and expectations. Such statements include, but are not limited to, statements regarding the completion, timing and size of the public offering, and the expected net proceeds therefrom.  Actual results may differ materially from those set forth in this press release due to the risks and uncertainties, including, without limitation, those associated with market conditions and the satisfaction of customary closing conditions related to the public offering, as well as those inherent in Cadence's business and finances in general, including the risks detailed in Cadence's prior press releases as well as in Cadence's periodic and other public filings with the SEC.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.  This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.  Contact:

William R. LaRue

Kelli FranceSVP & Chief Financial Officer


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
4. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
5. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
6. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
7. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
9. Cadence Pharmaceuticals CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
10. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
11. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
(Date:10/30/2014)... , Oct. 30, 2014 China Biologic Products, ... leading fully integrated plasma-based biopharmaceutical company in ... to release third quarter 2014 financial results on Wednesday, ... The Company,s management will hold a conference call ... 2014, which is 8:30 p.m., Beijing Time on November ...
(Date:10/30/2014)... October 30, 2014 , ... LGG contribuye a adquirir tolerancia a la proteína ... la proteína de la leche de la vaca (APLV) ... infancia. Hasta ahora, la APLV se trataba eliminando ... ha demostrado que es posible adquirir tolerancia oral ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3China Biologic to Report Third Quarter 2014 Financial Results 2SegĂșn expertos reunidos en el Simposio Allergy Day 2SegĂșn expertos reunidos en el Simposio Allergy Day 3
... 2010 Reportlinker.com announces that a new market research ... Toxicology and Pharmacology http://www.reportlinker.com/p0324751/Toxicology-and-Pharmacology.html ... Regulation; Technical, Political and Economic Challenges – key report ... are almost exclusively outsourced and the market is worth ...
... Nov. 3, 2010 Breast Cancer Action (BCA) learned today ... Lilly & Company via a billboard in Indianapolis have ... sick.  Tell them to stop" was rejected by every ... working within the guidelines of each billboard company contacted, ...
Cached Medicine Technology:Reportlinker Adds Toxicology and Pharmacology 2Reportlinker Adds Toxicology and Pharmacology 3Breast Cancer Message Barred in Eli Lilly's Hometown 2
(Date:10/31/2014)... HealthDay Reporter THURSDAY, Oct. 30, 2014 ... transplantation is nothing new. The first kidney transplant took ... 1963 and the first human heart transplant in 1967. By ... entire face. One major organ still eludes the transplant ... of U.S. scientists has its way, that dream may become ...
(Date:10/31/2014)... News) -- The number of medical malpractice payments in ... to a new study. And compensation payment amounts ... or declined in recent years, researchers report online Oct. ... Association . "For many physicians, the prospect of ... of modern clinical practice," researchers, led by Michelle Mello, ...
(Date:10/31/2014)... WASHINGTON, DC (October 31, 2014) — A new ... (Milken Institute SPH) at the George Washington University ... for pregnant women who are enrolled in Covered ... which includes the Comprehensive Perinatal Services Program (CPSP). ... the nation,s most successful programs ever developed for ...
(Date:10/30/2014)... day provide new treatments for injuries and damage to ... Cartilage, for example, is a hard material that caps ... smoothly. UC Davis biomedical engineers, exploring ways to toughen ... the body, report new developments this week in the ... . , "The problem with engineered tissue is that ...
(Date:10/30/2014)... group at the DFG Research Center for Regenerative Therapies ... (CRTD) demonstrated for the first time the in vitro ... dimensions from mouse embryonic stem cells. Correct spatial organization ... dorsal/ventral axis was observed., This study has been published ... Reports " on 30.10.2014 ., For many years Elly ...
Breaking Medicine News(10 mins):Health News:Scientists Set Their Sights on First Whole-Eye Transplant 2Health News:Scientists Set Their Sights on First Whole-Eye Transplant 3Health News:Fewer Malpractice Claims Paid in U.S. 2Health News:Report examines health care challenges for pregnant women enrolled in covered California 2Health News:Making lab-grown tissues stronger 2Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2
... that combines 2 medications , , SUNDAY, March 30 (HealthDay News) ... make sense of a trial showing that a drug can ... apparent benefit to people at high risk of heart attack ... well-known statin -- simvastatin -- with ezetimibe, which also lowers ...
... use with angioplasty following a heart attack, the anticoagulants ... measures within 90 minutes after the procedure, while patients ... a lower risk of major adverse cardiac events within ... to a JAMA study being released early online March ...
... risk and don,t increase mortality probability , , SUNDAY, March ... placed in diseased coronary arteries to keep them open, ... patients, new research shows. , In the largest study ... the drug in question retards the growth of arterial ...
... to Join Nation,s Largest RN ... Organization, ... registered nurses to have a stronger voice to speak,out for patients and ... to win union collective bargaining,rights., RNs at Cypress Fairbanks Medical Center ...
... deaths could be avoided with lifestyle changes, experts say, ... that could cut cancer deaths in half. , Well, ... American Cancer Society report that said as many as ... lifestyle changes, such as quitting smoking, maintaining a healthy ...
... mice was important protective mechanism, researchers say , , FRIDAY, March ... a critical role in protecting the heart during a heart ... It was already known that Gi increased activity in a ... helping the heart adapt to damage or if it actually ...
Cached Medicine News:Health News:Cholesterol Drug Controversy Continues 2Health News:Cholesterol Drug Controversy Continues 3Health News:Comparison of anticoagulants for angioplasty show similar outcomes 2Health News:Drug-Eluting Stents Safe After Heart Attack 2Health News:First Unionized Hospital in Texas 2Health News:First Unionized Hospital in Texas 3Health News:You May Be the Key to Cancer Prevention 2Health News:You May Be the Key to Cancer Prevention 3Health News:Key Protein Limits Damage of Heart Attack 2
World's first commercially available vacuum assisted biopsy device for MRI....
... you can perform stereotactic, ultrasound and MRI-guided ... of your office. Use the patented, FDA-cleared ... and more clinically advanced method of breast ... for the women who trust YOU.,9 Gauge ...
18" Penrose drains...
Offers a more constant suction profile than three-spring evacuators, resulting in the potential for improved tissue approximation and reduced risk of hematoma....
Medicine Products: